

Date Faxed: May 12, 2004

Sheet 1 of 4

| | | |
|---|-------------------------------------|--------------------------------|
| Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION | Docket Number: G&C 30435.152-US-11 | Application Number: 10/756,101 |
| | Applicant: Steven M. Dubinet et al. | |
| | Filing Date: January 13, 2004 | Group Art Unit 1616 |

U.S. PATENT DOCUMENTS - COPIES OF DOCUMENTS NOT REQUIRED

| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-------------------|----------|-----------------|-------|----------|-------------------------------|
| SM | 5,767,097 | 06/16/98 | Tam | | | |
| | 5,871,723 | 02/16/99 | Strieter et al. | | | |
| | 6,403,370 | 06/11/02 | Aleman et al. | | | |
| | US2002/0034494 A1 | 03/21/02 | Vicari et al. | | | |
| | US2003/0008840 A1 | 01/09/03 | Vicari et al. | | | |
| | US2003/0138413 A1 | 07/24/03 | Vicari et al. | | | |

FOREIGN PATENTS - COPIES OF DOCUMENTS NOT REQUIRED

| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|----|--------------|----------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| SM | WO 00/38706 | 07/06/00 | PCT | | | | |
| SM | WO 96/06169 | 02/29/96 | WIPO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) COPIES OF DOCUMENTS NOT REQUIRED

| | |
|----|--|
| SM | Arenberg et al., "Interferon-Gamma-Inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-Small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med., 1996, 184: 981-992. |
| SM | Arenberg et al., "The Murine CC Chemokine, 6C-kine, Inhibits Tumor Growth and Angiogenesis in a Human Lung Cancer SCID Mouse Model," Cancer Immunol. Immunother., 2001, 49: 587-592 |

| | |
|---|-------------------------|
| EXAMINER: <i>[Signature]</i> | DATE CONSIDERED: 2/2/07 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

* Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

G&C 30435.152-US-11

Date Filed: May 12, 2004

Sheet 2 of 4

| | | |
|---|--------------------------------------|--------------------------------|
| Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION | Docket Number: G&C 30435.152-US-11 | Application Number: 10/756,101 |
| | Applicant: Steven M. Dubinett et al. | |
| | Filing Date: January 13, 2004 | Group Art Unit: 1616 |

| | |
|--|---|
| | Baggiolini et al., "Human Chemokines: An Update," Ann. Rev. Immunol., 1997, 15: 675-705 |
| | Banchereau et al., "Dendritic Cells and the Control of Immunity," Nature, 1998, 392(6673): 245-252 |
| | Bellone et al., "Tumor-Associated Transforming Growth Factor- β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients," Am. J. Pathol., 1999, 155(2): 537-547 |
| | Brunda et al., "Antitumor and Antimetastatic Activity of Interleukin 12 Against Murine Tumors," J. Exp. Med., 1993, 178: 1223-1230 |
| | Chan et al., "Secondary Lymphoid-Tissue Chemokine (SLC) Is Chemotactic for Mature Dendritic Cells," Blood, 1999, 93(11): 3610-3616 |
| | Chu et al., "Examining the Immune Response in Sentinel Lymph Nodes of Mice and Men," Eur. J. Nuc. Med., 1999, 26(Supplement): s50-53 |
| | Cyster, "Chemokines and the Homing of Dendritic Cells to the T Cell Areas of Lymphoid Organs," J. Exp. Med., 1999, 189(3): 447-450 |
| | Dieu et al., "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med., 1998, 188(2): 373-386 |
| | D. Dilloo et al., "Combined chemokine and cytokine gene transfer enhances antitumor immunity," Nature Medicine, Vol. 2, No. 10, October 1996, pages 1090-1095 |
| | S. Dubinett et al., "Gene Therapy for Lung Cancer," Gene Therapy, 1998, 12(3): 569-594 |
| | Fajardo et al., "Transforming Growth Factor β 1 Induces Angiogenesis In Vivo With a Threshold Pattern," Lab. Invest., 1996, 74(3): 600-608 |
| | Farber, "Mig and IP-10: CXC Chemokines That Target Lymphocytes," J. Leukoc. Biol., 1997, 61(3): 246-257 |
| | Ferrara, "The Role of Vascular Endothelial Growth Factor in Pathological Angiogenesis" Breast Cancer Res. Treat., 1995, 36: 127-137 |
| | Gabrilovich et al., "Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells," Nat. Med., 1996, 2(10): 1096-1103 |
| | Halak et al., "Tumor-Induced Interleukin-10 Inhibits Type 1 Immune Responses Directed at a Tumor Antigen As Well As a Non-Tumor Antigen Present at the Tumor Site," Cancer Res., 1999, 59: 911-917 |
| | Hedrick et al., "Identification and Characterization of a Novel β Chemokine Containing Six Conserved Cysteines," J. Immunol., 1997, 159: 1589-1593 |

| | |
|--|-------------------------|
| EXAMINER: | DATE CONSIDERED: 2/8/07 |
| EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 30435.152-US-11

Date Faxed: May 12, 2004

Sheet 3 of 4

| | | |
|---|--------------------------------------|--------------------------------|
| Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION | Docket Number: G&C 30435.152-US-11 | Application Number: 10/756,101 |
| | Applicant: Steven M. Dubinett et al. | |
| | Filing Date: January 13, 2004 | Group Art Unit: 1616 |

| | |
|----|--|
| SP | Hromas et al., "Isolation and Characterization of Exodus-2, a Novel C-C Chemokine with a Unique 37-Amino Acid Carboxyl-Terminal Extension," J. Immunol., 1997, 159: 2554-2558 |
| | Hu et al., "Gene Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile," J. Immunol., 1998, 161: 3033-3041 |
| | Huang et al., "Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Regulation of Cytokine Balance in Lymphocytes..." Cancer Res., 1998, 58(6): 1208-1216 |
| | Jenb et al., "Cutting Edge: Species Specificity of the CC Chemokine 6Ckine Signaling Through the CXCR Chemokine..." J. Immunol., 1999, 162: 3765-3769 |
| | Johnson et al., "Interleukin-12, Dendritic Cells, and the Initiation of Host-Protective Mechanisms Against <i>Toxoplasma Gondii</i> ," J. Exp. Med., 1997, 186(11): 1799-1802 |
| | Kellermann et al., "The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3 β Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells," J. Immunol., 1999, 162: 3859-3864 |
| | Loetscher et al., "Chemokine Receptor Specific for IP-10 and Mig: Structure, Function, and Expression in Activated T-Lymphocytes," J. Exp. Med., 1996, 184: 963-969 |
| | Luster et al., "IP-10, a C-X-C- Chemokine, Elicits a Potent Thymus-Dependent Antitumor Response In Vivo," J. Exp. Med., 1993, 178: 1057-1065 |
| | Magdalena et al., "Cyclin-Dependent Kinase Inhibitor Expression in Pulmonary Clara Cells Transformed with SV40 Large T Antigen in Transgenic Mice," Cell Growth & Diff., 1997, 8(2): 145-155 |
| | Nagira et al., "Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That Is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13," J. Biol. Chem., 1997, 272(31): 19518-19524 |
| | Nanda et al., "Induction of anti-self-immunity to cure cancer: meeting review; gene therapy, adoptive immunotherapy and antitumor recombinant vaccine production (conference report)", abstract, Cell, Vol. 82, No. 1, 1995, pages 13-17. Database Biotechds, Accession Number 1995-12009. |
| | Ogata et al., "Chemotactic Response Toward Chemokines and its Regulation by Transforming Growth Factor- β 1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells," Blood, 1999, 93(10): 3225-3232 |
| | Sallusto et al., "Rapid and Coordinated Switch in Chemokine Receptor Expression During Dendritic Cell Maturation," Eur. J. Immunol., 1998, 28: 2760-2769 |
| ✓ | S. Sharma et al., "Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo," J. of Immunology, 2000, 164: 4558-4563 |

| | |
|--|-------------------------|
| EXAMINER: <i>[Signature]</i> | DATE CONSIDERED: 2/8/07 |
| EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 30435.152-US-11

Date Faxed: May 12, 2004

Sheet 4 of 4

| | | |
|---|--------------------------------------|--------------------------------|
| Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION | Docket Number: G&C 30435.152-US-11 | Application Number: 10/756,101 |
| | Applicant: Steven M. Dubinett et al. | |
| | Filing Date: January 13, 2004 | Group Art Unit: 1616 |

| | |
|----|--|
| Se | Sharma et al., "T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function," J. Immunol., 1999, 163: 5020-5028 |
| | S. Sharma et al., "Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma," Cancer Research, 2001, 61: 6406-6412 |
| | Soto et al., "The CC Chemokine 6Ckine Binds the CXC Chemokine Receptor CXCR3," PNAS, USA, 1998, 95(14): 8205-8210 |
| | Sozzani et al., "Cutting Edge: Differential Regulation of Chemokine Receptors During Dendritic Cell Maturation: A model for Their Trafficking Properties," J. Immunol., 1998, 161: 1083-1086 |
| | Stolina et al., "Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis," J. Immunol., 2000, 164: 361-370 |
| | Strieter et al., "Interferon γ -Inducible Protein 10(IP-10), A Member of the C-X-C Chemokine Family, Is an Inhibitor of Angiogenesis," Biochem. Biophys. Res. Commun., 1995, 210(1): 51-57 |
| | Sun et al., "Interleukin-10 Gene Transfer Activates Interferon- γ and the Interferon- γ -Inducible Genes Gbp-1/Mag-1 and Mig-1 in Mammary Tumors," Int. J. Cancer, 1999, 80: 624-629 |
| | Tanabe et al., "Identification of a New Mouse β -Chemokine, Thymus-Derived Chemotactic Agent 4, with Activity on T Lymphocytes and Mesangial Cells," J. Immunol., 1997, 159: 5671-5679 |
| | Tannenbaum et al., "The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor," J. Immunol., 1998, 161: 927-932 |
| | Tsuji et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells," Cell, 1998, 93: 705-716 |
| | Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12," J. Natl. Cancer Inst., 1995, 87(8): 581-586 |
| | Willmann et al., "The Chemokine SLC is Expressed in T Cell Areas of Lymph Nodes and Mucosal Lymphoid Tissues and Attracts Activated T Cells Via CCR7," Eur. J. Immunol., 1998, 28: 2025-2034 |
| | Yoshida et al., "Secondary Lymphoid-Tissue Chemokine is a Functional Ligand for the CC Chemokine Receptor CCR7," J. Biol. Chem., 1998, 273(12): 7118-7122 |
| | |
| | |
| | |
| | |

| | |
|---|--------------------------------|
| EXAMINER: <i>[Signature]</i> | DATE CONSIDERED: <i>2/8/08</i> |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

G&C 30435.152-US-11